As of 2025-07-12, the EV/EBITDA ratio of Crinetics Pharmaceuticals Inc (CRNX) is -7.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CRNX's latest enterprise value is 2,896.63 mil USD. CRNX's TTM EBITDA according to its financial statements is -374.03 mil USD. Dividing these 2 quantities gives us the above CRNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.1x - 13.3x | 10.7x |
| Forward P/E multiples | 12.3x - 20.5x | 16.4x |
| Fair Price | (48.10) - (52.09) | (53.09) |
| Upside | -250.6% - -263.1% | -266.3% |
| Date | EV/EBITDA |
| 2025-07-11 | -7.80 |
| 2025-07-10 | -7.76 |
| 2025-07-09 | -7.84 |
| 2025-07-08 | -7.10 |
| 2025-07-07 | -7.03 |
| 2025-07-03 | -7.21 |
| 2025-07-02 | -7.12 |
| 2025-07-01 | -6.87 |
| 2025-06-30 | -6.95 |
| 2025-06-27 | -7.25 |
| 2025-06-26 | -7.26 |
| 2025-06-25 | -7.36 |
| 2025-06-24 | -7.50 |
| 2025-06-23 | -7.24 |
| 2025-06-20 | -7.30 |
| 2025-06-18 | -7.39 |
| 2025-06-17 | -7.47 |
| 2025-06-16 | -7.56 |
| 2025-06-13 | -7.70 |
| 2025-06-12 | -7.80 |
| 2025-06-11 | -7.84 |
| 2025-06-10 | -8.03 |
| 2025-06-09 | -7.83 |
| 2025-06-06 | -8.01 |
| 2025-06-05 | -7.84 |
| 2025-06-04 | -7.79 |
| 2025-06-03 | -7.79 |
| 2025-06-02 | -7.73 |
| 2025-05-30 | -7.39 |
| 2025-05-29 | -7.39 |
| 2025-05-28 | -7.24 |
| 2025-05-27 | -7.14 |
| 2025-05-23 | -7.20 |
| 2025-05-22 | -7.29 |
| 2025-05-21 | -7.25 |
| 2025-05-20 | -7.60 |
| 2025-05-19 | -7.50 |
| 2025-05-16 | -7.57 |
| 2025-05-15 | -7.56 |
| 2025-05-14 | -7.58 |
| 2025-05-13 | -7.50 |
| 2025-05-12 | -8.09 |
| 2025-05-09 | -7.43 |
| 2025-05-08 | -7.94 |
| 2025-05-07 | -7.61 |
| 2025-05-06 | -7.39 |
| 2025-05-05 | -8.18 |
| 2025-05-02 | -8.20 |
| 2025-05-01 | -8.14 |
| 2025-04-30 | -8.11 |